On Tuesday, Sarepta Therapeutics, Inc. SRPT stock is sliding. The company shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy.The company reported a patient death following treatment with Elevidys, having suffered acute liver failure.Acute liver injury is a known possible side effect of Elevidys and other AAV-mediated gene therapies and is highlighted in the prescribing information.Also Read: Solid Biosciences Outpaces ...

I've been writing for Seeking Alpha since 2017 with a focus on healthcare and technology investments. With a background as a Registered Nurse, I analyze biotech stocks by evaluating clinical data, treatment guidelines, and market dynamics. My MBA provided a foundation of financial theory, allowing me to expand into technology investments, where I focus on identifying key valuation drivers and using DCF modeling for scenario-based forecasts. My thinking is influenced by books such as "Superforecasting" and " ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number : 001-14895 Sarepta Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 93-0797222 (State or other jurisdi ...

Sarepta Therapeutics, Inc. (SRPT) reported fourth-quarter 2024 earnings per share (EPS) of $1.50, which missed the Zacks Consensus Estimate of $1.87. However, the reported figure was significantly higher than the year-ago period’s 47 cents due to higher product sales.The loss included depreciation and amortization costs and stock-based compensation expenses. The adjusted EPS in the quarter was $1.90 compared with 82 cents in the year-ago period.Sarepta recorded total revenues of $658.4 million, up 66% year ...

Financial Data and Key Metrics Changes - For Q4 2024, the company reported total revenues of $658.4 million, an increase of $261.6 million compared to $396.8 million in Q4 2023 [64] - Net product revenue for Q4 2024 was $638 million, growing 75% year-over-year, and full-year net product revenue reached $1.8 billion, representing a 56% increase [14][64] - The company achieved a GAAP net income of $159 million for Q4 2024, compared to $45.7 million in Q4 2023, and a non-GAAP net income of $206 million, up from $86.6 million [66] Business Line Data and Key Metrics Changes - ELEVIDYS sales for Q4 2024 were $384.2 million, a 112% increase from the previous quarter, and total sales since its launch exceeded $1 billion [15][28] - The PMO franchise generated $254 million in Q4 2024, growing approximately 9% compared to Q4 2023, with individual revenues of $137.6 million for EXONDYS 51, $40.2 million for VYONDYS 53, and $76.2 million for AMONDYS 45 [31][32] Market Data and Key Metrics Changes - The company noted that ELEVIDYS has only treated about 5% of the on-label addressable patient population, indicating significant growth potential ahead [33][41] - The PMO franchise continues to perform well, growing organically without price increases, reflecting an increase in patients served in the Duchenne community [30] Company Strategy and Development Direction - The company aims to build on the success of Project Moonshot, focusing on expanding its gene therapy pipeline and achieving multiple potential blockbuster siRNA launches by the end of the decade [9][13] - The strategic collaboration with Arrowhead is expected to diversify the company's future, adding a broad platform of siRNA programs across various diseases [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the 2025 net product revenue guidance of $2.9 billion to $3.1 billion, representing a 70% year-over-year growth [17][42] - The company anticipates continued quarter-over-quarter growth throughout 2025, driven by strong demand for ELEVIDYS and the PMO franchise [81] Other Important Information - The company plans to transition to suspension manufacturing to improve cost of goods sold (COGS) and is preparing for multiple upcoming clinical milestones in 2025 [20][21] - The company has approximately $1.5 billion in cash and investments as of December 31, 2024, and secured a $600 million revolving credit facility to support its strategic goals [71][72] Q&A Session Summary Question: What is the cadence of patient onboarding in Q1? - Management reiterated confidence in guidance for 2025, expecting growth quarter-over-quarter as the launch ramps up [80] Question: What is the prevalence of limb-girdle muscular dystrophy type 2E? - Management indicated that type 2E is an ultra-rare disease, with a 50-50 split between ambulatory and non-ambulatory patients [85][87] Question: Will the upcoming data for FSHD and DM1 be conclusive? - Management stated that the initial single ascending dose (SAD) data will provide important proof of biology, but further data will be needed for definitive conclusions [108][110] Question: What is the status of reimbursement for PMOs in ELEVIDYS treated patients? - Management noted early signs of reimbursement for both therapies, but emphasized that it is still early days to draw broad conclusions [115][117] Question: What is the timeframe for the $500 million share repurchase program? - The program has an 18-month timeframe, and management plans to be opportunistic in deploying capital as cash reserves are built back up [125][126]

Financial Performance - Total product revenue for FY 2024 reached $1788 million, a 56% increase compared to $1145 million in FY 2023[39] - Q4 2024 total product revenue was $638 million, a 75% increase compared to $365 million in Q4 2023[38] - Sarepta achieved GAAP operating income of $218 million in FY 2024, compared to a loss of $268 million in FY 2023[39] - Non-GAAP operating income for FY 2024 was $438 million, compared to a loss of $42 million in FY 2023[39] - The company secured a $600 million revolving credit facility[13, 37] - Sarepta announced a $500 million share repurchase program[13] Product Performance - ELEVIDYS launch contributed to strong revenue growth, with Q4 revenue exceeding guidance by over $60 million and growing 112% over the previous quarter[19] - PMO products remained a steady contributor to net product revenue[13] Future Outlook - Sarepta anticipates total product revenue between $2900 million and $3100 million for FY 2025, representing approximately 68% growth at the midpoint[40] - Combined Non-GAAP R&D and SG&A expenses are projected to be between $1200 million and $1300 million for FY 2025[40]

Financial Data and Key Metrics Changes - For Q4 2024, the company reported total revenues of $658.4 million, an increase of $261.6 million compared to $396.8 million in Q4 2023 [64] - Net product revenue for Q4 2024 was $638 million, growing 75% year-over-year, and full-year net product revenue was $1.8 billion, representing a 56% increase [14][64] - The company achieved a GAAP net income of $159 million for Q4 2024, compared to $45.7 million in Q4 2023, and a non-GAAP net income of $206 million, up from $86.6 million [67] Business Line Data and Key Metrics Changes - ELEVIDYS sales for Q4 2024 were $384.2 million, a 112% increase from the previous quarter, and total sales since approval exceeded $1 billion [15][28] - The PMO franchise generated $254 million in Q4 2024, growing approximately 9% compared to Q4 2023, with individual revenues of $137.6 million for EXONDYS 51, $40.2 million for VYONDYS 53, and $76.2 million for AMONDYS 45 [31][32] Market Data and Key Metrics Changes - The company noted that ELEVIDYS has only treated about 5% of the on-label addressable patient population, indicating significant growth potential ahead [33][114] - The PMO franchise continues to perform well, growing organically without price increases, reflecting an increase in patients served in the Duchenne community [30] Company Strategy and Development Direction - The company aims to build on the success of Project Moonshot, focusing on expanding its gene therapy pipeline and achieving multiple potential blockbuster siRNA launches by the end of the decade [9][13] - The strategic collaboration with Arrowhead is expected to diversify the company's future, adding a broad platform of siRNA programs across various therapeutic areas [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 2025 net product revenue guidance of $2.9 billion to $3.1 billion, representing approximately 70% growth over 2024 [42] - The company anticipates continued growth quarter-over-quarter throughout 2025, driven by the strong performance of ELEVIDYS and the PMO franchise [81] Other Important Information - The company plans to transition to suspension manufacturing to improve cost of goods sold (COGS) and has several significant milestones expected in 2025 [20][21] - The company has approximately $1.5 billion in cash and investments as of December 31, 2024, and secured a $600 million revolving credit facility [72][73] Q&A Session Summary Question: What is the cadence of patient onboarding in Q1? - Management reiterated confidence in guidance for 2025, expecting growth quarter-over-quarter as the launch ramps up [80] Question: What is the prevalence of limb-girdle muscular dystrophy type 2E? - Management indicated that type 2E is an ultra-rare disease, with a 50-50 split between ambulatory and non-ambulatory patients [85][87] Question: Will the upcoming data for FSHD and DM1 be conclusive? - Management emphasized the importance of early data as proof of biology, with expectations for safety and efficacy signals [108][110] Question: What is the status of ELEVIDYS and PMO reinvestment? - Management noted early days for drawing conclusions on reinvestment but indicated some instances of reimbursement for both therapies [116] Question: What is the timeframe for the $500 million share repurchase program? - The program has an 18-month timeframe, with plans to be opportunistic in deploying capital as cash reserves are built back up [124]

Core Viewpoint - Sarepta Therapeutics reported quarterly earnings of $1.50 per share, missing the Zacks Consensus Estimate of $1.87 per share, representing an earnings surprise of -19.79% [1] - The company posted revenues of $658.41 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 2.83% and showing a significant increase from $396.78 million year-over-year [2] Financial Performance - Earnings per share (EPS) for the current quarter was $1.50, compared to $0.47 per share a year ago [1] - The company has surpassed consensus EPS estimates three times over the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is $1.73, with expected revenues of $656.12 million, and for the current fiscal year, the EPS estimate is $10.94 on revenues of $3.03 billion [7] Market Performance - Sarepta Therapeutics shares have declined approximately 12% since the beginning of the year, while the S&P 500 has gained 1.3% [3] - The company's Zacks Rank is currently 2 (Buy), indicating expectations of outperforming the market in the near future [6] Industry Outlook - The Medical - Biomedical and Genetics industry is currently in the top 24% of over 250 Zacks industries, suggesting a favorable outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Viewpoint - Sarepta Therapeutics (SRPT) has experienced a bearish trend, losing 9% over the past four weeks, but the formation of a hammer chart pattern suggests a potential trend reversal as buying interest may be increasing [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottoming out, with reduced selling pressure, suggesting that bulls may be gaining control [2][4]. - A hammer pattern forms when there is a small candle body with a long lower wick, indicating that despite a downtrend, buying interest emerges at lower prices, pushing the stock up to close near its opening price [3][4]. - This pattern can occur across various timeframes and is utilized by both short-term and long-term investors [4]. Fundamental Analysis - There has been a positive trend in earnings estimate revisions for SRPT, which is a bullish indicator, as it typically leads to price appreciation [6]. - The consensus EPS estimate for the current year has increased by 8.3% over the last 30 days, indicating strong agreement among analysts regarding the company's improved earnings potential [7]. - SRPT holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which historically outperform the market [8].

Core Viewpoint - Sarepta Therapeutics (SRPT) has experienced significant selling pressure, resulting in an 8.5% decline in stock price over the past four weeks, but analysts anticipate better earnings than previously predicted, indicating potential for recovery [1]. Group 1: Technical Analysis - The Relative Strength Index (RSI) is utilized to identify oversold stocks, with a reading below 30 typically indicating oversold conditions [2]. - SRPT's current RSI reading is 29.78, suggesting that the heavy selling may be exhausting itself and a trend reversal could be imminent [5]. - The RSI serves as a momentum oscillator, helping investors identify potential entry points for stocks that have fallen below their fair value due to excessive selling pressure [3]. Group 2: Fundamental Analysis - Analysts have raised earnings estimates for SRPT by 10.1% over the last 30 days, indicating a strong consensus among sell-side analysts and suggesting potential price appreciation [6]. - SRPT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the stock's potential for a turnaround [7].